China Pharma Holdings (CPHI) Price to Sales (2010 - 2026)

China Pharma Holdings (CPHI) has reported Price to Sales for 17 consecutive years, with 28.2 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 395.43% year-over-year to 28.2; the trailing twelve-month figure through Jun 2026 stood at 6.83 (up 414.45% YoY), and the FY2025 full-year result was 1.25, up 39.76% from the prior year.
• Price to Sales rose to 28.2 in Q2 2026 per CPHI's latest filing, from 15.88 in the prior quarter.
• Across five years, Price to Sales topped out at 28.2 in Q2 2026 and bottomed at 0.95 in Q4 2023.
• Historically, Price to Sales has averaged 6.52 across 5 years, with a median of 4.12 in 2025.
• The sharpest annual moves came in 2023 and 2026: Price to Sales slumped 85.68% in 2023, then jumped 395.43% in 2026.
• Over 5 years, Price to Sales stood at 1.73 in 2022, then slumped by 44.82% to 0.95 in 2023, then surged by 276.0% to 3.58 in 2024, then rose by 18.29% to 4.24 in 2025, then jumped by 565.84% to 28.2 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 28.2, 15.88, and 4.24 for Q2 2026, Q1 2026, and Q4 2025 respectively.